

Erlotinib PA.3

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**

OS



### ADJUSTMENTS

**Quality of life**



No QoL benefit

**Serious and disabling adverse effects**



**Other adjustments**



Erlotinib PA.3

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**

1



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Gastrointestinal Cancers  
 Therapeutic Indication: Erlotinib in combination with gemcitabine for the treatment of patients with metastatic pancreatic cancer  
 Experimental Arm: Erlotinib + Gemcitabine  
 Control Arm: Gemcitabine + placebo

